Replies to post #69282 on Regen BioPharma Inc (RGBP)

[Carter]

Regen BioPharma, Inc. Discovers Fundamental Role of NR2F6 in Production of Malignant Blood Vessels

Laboratory Data and Patent Filing Supports Possible Treatments for Wet Macular
Degeneration and Cancer

PR Newswire

SAN DIEGO, Nov. 1, 2019

SAN DIEGO, Nov. 1, 2019 /PRNewswire/ -- Regen BioPharma, Inc. (OTC PINK:
RGBP) (OTC PINK: RGBPP) announced today new data demonstrating that
suppression of NR2F6 using patent-pending compounds developed by the Company
results in selective inhibition of new blood vessels under conditions
associated with cancer and wet macular degeneration. The data, which was
obtained using human umbilical vein endothelial cells (HUVEC), indicates that
NR2F6 may have a larger biological role than originally suspected.

Regen BioPharma, Inc. has been utilizing NR2F6 as a target for immune
modulation and cancer stem cells. To the Company's knowledge, this is the
first indication to date that NR2F6 is involved in the formation of new blood
vessels.

"New blood vessels are typically not formed in an adult except in conditions
such as cancer (in which the tumor cells require a new blood supply) or in wet
macular degeneration; a condition in which new blood vessels result in
impairment of vision," said Thomas Ichim, PhD, co-inventor of the patent and
consultant to the Company. "In our experiments, we observed that inhibition of
NR2F6 selectively blocked multiplication of blood vessel cells that were
stimulated with Vascular Endothelial Growth Factor (VEGF). Since VEGF is
associated with disease conditions, it is possible that our approach possesses
some degree of specificity in blocking pathological but not healthy formation
of new blood vessels. New blood vessels suggests that this approach may not
suppress healthy blood vessels which are primarily formed independently of
VEGF."

Drugs which target VEGF as a means of suppressing pathological blood vessel
formation include Avastin (Sales $2.8 Billion in 2018^1) for cancer and
Lucentis (Sales $1.9 Billion in 2018^2).

"What this data demonstrates is a potential mechanism to kill cancer cells
without the toxicity associated with conventional treatments," noted the
Company's Chairman & CEO David Koos. "We believe this coupled with our current
small molecule therapies as a quality additional approach to treating cancer."

https://www.bloomberg.com/press-releases/2019-11-01/regen-biopharma-inc-discovers-fundamental-role-of-nr2f6-in-production-of-malignant-blood-vessels

[RHF469usa]

GOGGLE IT,IT'S EASY

[Madguppy]

Put " What is NR2F6" in Google search bar and here is what came up first.

"V-erbA-related protein 2 (EAR-2) also known as NR2F6 (nuclear receptor subfamily 2 group F member 6) is a protein that in humans is encoded by the NR2F6 gene........"

"It was found that expression of NR2F6 was consistently upregulated in neoplastic tissues in leukemic, ovarian cancer and endometrial cancer"..........

"The company that owns the patent on this would be worth gaaaaazillions"

Ok, made up last quote, but found a lot of info way over this smooth brain, but it seems big.


So, to quote a wrinkly brain......"double dog dare ya" to Google this and not be impressed.